Dolutegravir + Lopinavir/Ritonavir = Unknown or no reaction

Effect on Concentration

Dolutegravir
No change
Applies within class?
No
Lopinavir/Ritonavir
No change
Applies within class?
No

Pharmacologic Effects

Dolutegravir
Effect
N/A
Applies within class?
No
Lopinavir/Ritonavir
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 13-Jul-2018

Summary

Sources

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. ^

Study Design

This was a randomized, open-label, 2-period, 2-sequence crossover study conducted in healthy adults. All participants received dolutegravir (DTG) 30mg QD for 5 days in the first treatment period. In the second treatment period, participants then received DTG 30mg QD plus either lopinavir/ritonavir (LPV/r) 400/100mg Q 12h, or darunavir/ritonavir (DRV/r) 600/100mg Q 12h for 14 days, with no washout period in between. All doses were administered within 30 minutes of a moderately fatty meal. Blood samples for pharmacokinetic (PK) analysis were obtained on the last day of each treatment period.

Study Results

The geometric mean ratio (90% confidence interval) for the AUC, Cmax, and Cmin were 0.97 (90%CI 0.91-1.04), 1.00 (90%CI 0.94-1.07) and 1.02 (90%CI 0.88-1.17) respectively. No dose adjustment is necessary.

Study Conclusions

Co-administration of DTG + LPV/r had no effect on the steady state DTG PK when compared to DTG alone.

References

Song I, Borland J, Min SS. The effect of lopinavir/ritonavir and darunavir/ritonavir on the hiv integrase inhibitor s/gsk1349572 in healthy participants. Journal Of Clinical Pharmacology. 2011; 2: 237-242.